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Abstract
Background, cancer significance and question—BioProspecting is a novel approach that 
enabled our team to mine genetic marker related data from the New England Journal of Medicine 
(NEJM) utilizing Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT) and the 
Human Gene Ontology (HUGO). Genes associated with disorders using the Multi-threaded 
Clinical Vocabulary Server (MCVS) Natural Language Processing (NLP) engine, whose output 
was represented as an ontology-network incorporating the semantic encodings of the literature. 
Metabolic functions were used to identify potentially novel relationships between (genes or 
proteins) and (diseases or drugs). In an effort to identify genes important to transformation of 
normal tissue into a malignancy, we went on to identify the genes linked to multiple cancers and 
then mapped those genes to metabolic and signaling pathways.
Findings—Ten Genes were related to 30 or more cancers, 72 genes were related to 20 or more 
cancers and 191 genes were related to 10 or more cancers. The three pathways most often 
associated with the top 200 novel cancer markers were the Acute Phase Response Signaling, the 
Glucocorticoid Receptor Signaling and the Hepatic Fibrosis/Hepatic Stellate Cell Activation 
pathway.
Meaning and implications of the advance—This association highlights the role of 
inflammation in the induction and perhaps transformation of mortal cells into cancers.
Major findings—BioProspecting can speed our identification and understanding of synergies 
between articles in the biomedical literature. In this case we found considerable synergy between 
the Oncology literature and the Sepsis literature. By mapping these associations to known 
metabolic, regulatory and signaling pathways we were able to identify further evidence for the 
inflammatory basis of cancer.
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Introduction
The Genomics and Bioinformatics research communities have been successful over the past 
several years in discovering of the genetic basis of Mendelian disorders [1]. Computational 
tools delivered by the field of Bioinformatics have been essential in our search for the 
genetic basis of Mendelian disease [2]. Bioinformatics research develops technologies in the 
context of clinical and genetic data standards that have been employed to create linkages 
between genes and disorders [3]. Unfortunately, many diseases cannot be traced to a single 
genetic variation where the true origin of a disease is a complex interplay of genetic 
variations, environmental factors, and “lifestyle” characteristics, along with some stochastic 
processes [4]. To advance medical science and healthcare, a broader understanding of 
genetic markers and their inter-relationships is required [5]. Our project to “discover” a 
genetic marker by mining the medical literature was an attempt to reveal, and later research, 
linkages between variants discerned through the mining of the medical literature [6].
New England Journal of Medicine (NEJM)
The NEJM is considered one of the highest impact peer-reviewed medical journals [7]. 
NEJM is the oldest continuously published medical journal. In 1812, the journal was 
inaugurated as the New England Journal of Medicine and Surgery [8]. The NEJM, in 1928, 
took on its present name after one hundred years as The Boston Medical and Surgical 
Journal.
The commontary associated with the presentation of the George Polk Award noted that its 
1977 award to the New England Journal of Medicine “provided the first significant 
mainstream visibility for a publication that would achieve enormous attention and prestige in 
the ensuing decades” [9].
The NEJM publishes papers on original research, widely cited editorials, review articles, 
correspondences and case reports. The NEJM consistently has the highest impact factor of 
the journals of clinical medicine and in 2010 it was 53.48.
The NEJM provides on-line (electronic) access. Our study included the full text of all 
articles from January 1994 through December 2006.
SNOMED CT (Systematized Nomenclature of Medicine-Clinical Terms)
SNOMED CT (SCT) is a large-scale general medical ontology used to describe current 
medical and health knowledge [10]. We employed SCT to represent clinical disorders, 
proteins, chemicals and metabolic functions identified within the biomedical literature. SCT 
is the most comprehensive of the general medical and biological Ontologies. SCT is 
maintained by the International Heath Terminology Standards Development Organization 
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(IHTSDO) and is designed to represent the health and medical domains. Although very 
broad with over 291,000 concepts and over 1.2 million relations, it does not provide 
complete coverage of all medical content. SCT was formed through a merger of SNOMED 
RT (Reference Terminology) in the late 1990s with another large ontology, Clinical Terms 
v3, developed in the United Kingdom.
Ontologies, to be practically useful for computation, need to be accurate in two specific 
ways; firstly, they need to match as closely as possible our understanding of the natural 
world. Secondly, ontologies need to be at least 95% complete in their domain coverage. This 
means the ontology needs to be constructed with very close attention to the meanings of its 
concepts. In other words the concepts used in the ontology need to represent closely the 
understanding we have of the real world [11]. The variety of linguistic “usage” of those 
terms needs to be harnessed to ensure that the ontology has adequate content coverage. One 
should adequately explore the diversity of semantic roles of the concepts to ensure that only 
those roles that are useful are included in the ontological modeling, and to remove ambiguity 
in the use of those roles. Precision of each definition is particularly important in establishing 
the relationships between concepts and identifying the fundamental atomic concepts and 
how they combine or “fit together” systematically in compositional expressions. Ontologies 
also consist of levels of abstractions. In ontological computation there are two basic forms of 
abstraction, aggregation and generalization. Aggregation hierarchies are created from the 
ontological indexing by linking like objects. Generalization hierarchies are used throughout 
SCT as the basic mechanisms for relating content (e.g. All Oncological disorders).
SCT provides concepts to represent diagnoses, findings, procedures and testing. In a 
previous article we Elkin et al. published a cohort study reporting that SCT provided 92.3% 
coverage of common medical problems from cases from the Mayo Clinic [12]. This NLP 
system has been used in subsequent studies for electronic quality monitoring [13].
HUGO
The Human Genome Organization (HUGO) is an organization involved in the Human 
Genome Project. HUGO was established to foster collaboration between genome scientists 
around the world, in 1989. The HUGO Gene Nomenclature Committee (HGNC) is one of 
HUGO’s committees that assign a unique gene name and symbol for each human gene.
Materials and Methods
We parsed the full-text content of the New England Journal of Medicine (1994-2006) using 
the Multi-threaded Clinical Vocabulary Server. The MCVS creates an ontology-network of 
the semantic encodings of genes, proteins, disorders and drugs and metabolic functions 
identified in the literature that are organized by the section of the article including the tables.
The indexing was done utilizing SNOMED-CT and the HUGO Ontologies. We utilized 
SNOMED CT as it provides robust clinical indexing. SNOMED-CT has >370,000 concepts 
and >1,000,000 terms (in our lab we added another 790,000 terms to improve its clinical 
relevance) and HUGO has >26,000 human gene names. This concept based indexing 
represents a broad and consistent data infrastructure across articles from the literature [14].
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We identified co-occurrences of genes and metabolic functions, proteins and metabolic 
functions, diseases and metabolic functions and drugs and metabolic functions. Next, we 
matched these data sets linking pairs (e.g. Disorders and Genes) with a common metabolic 
function, identifying functional relationships between proteins and diseases, for example. 
Candidate functional relationships were identified between genes and diseases, proteins and 
drugs, genes and drugs, and drugs and diseases. Next, we identified the disjoint sets where, 
for example, a gene and a disease match across metabolic function but have not been 
mentioned together in any previous NEJM journal article.
We compiled the genes from the disjoint set (potentially novel markers) that were related to 
more than three tissue types of cancer. We sorted the genes by the number of cancers 
associated with the gene. Then we took the 200 genes from the top of this list and mapped 
them against the metabolic pathways and signaling pathways available within Ingenuity™ 
[15]. Ingenuity is commercially available pathway analysis software. The pathways 
associated with the highest number of these possibly novel genes are reported.
We compared the chance that a gene would be related to 20 or more cancers and by random 
chance with the rate of identification in our study and analyzed the results using the 
McNemar test.
The conceptual process can be visualized as shown in Figure 1.
Results
Novel relationships
SCT contained 574 metabolic functions that were used to link to Genes, Proteins, Disorders, 
and Drugs.
We identified 1756 genes that were related to 10,303 different types of cancer. Ten genes 
were related to 30 or more cancers. The gene associated with the most cancers was 
MYELIN OLIGODENDROCYTE GLYCOPROTEIN and was related to 35 types of cancer. 
There were 72 genes related to 20 or more cancers and there were 191 genes related to 10 or 
more cancers. We have annotated the top 50 genes and present them in table 1. In table 2 we 
show the clinical pathways containing the top 200 genes from this dataset and which we 
then mapped against the metabolic and signaling pathways (See Table 2) to identify the most 
common pathways that involved this set of genes. The pathways with the greatest overlap 
with this dataset were the Acute Phase Response Signaling pathway (See Figure 2) 
respectively, the Glucocorticoid Receptor Signaling and the Hepatic Fibrosis/Hepatic 
Stellate Cell Activation pathway that includes targets such as TNFa-NFkB.
The chance that a gene is related to twenty or more cancers as identified by our 
bioprospecting method and is not truly related to cancer is very small (that all findings 
would be false positives; 3.9 ×10-24:1). If we compare the chance that a gene would be 
related to twenty or more cancers based on chance alone with the current findings the results 
are highly statistically significant (p<0.001; McNemar Test).
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The biomedical literature is a repository of our accumulated biomedical knowledge. Much 
of the value contained in this resource is locked in free-text and is therefore not in a form 
that is easily amenable to computational analysis. Biomedical researchers cannot practically 
keep up with the entirety of the biomedical literature. Natural language processing has the 
potential to unlock the knowledge within the freetext medical literature. In this experiment 
we used the information from the NEJM, one of the premier medical journals, to determine 
if novel relationships could be identified between Genes, Proteins, Drugs and Disorders. 
These relationships are indeed prevalent and hold tremendous potential to increase our 
understanding of human disease.
We examined all of the genes related to more than three cancers. In this analysis we have 
identified 10 genes related to thirty or more cancers, 72 genes related to twenty or more 
cancers and 191 genes related to ten or more cancers. It is possible, that the genes in table 
two will serve to help researchers identify the cure for cancer. We then mapped the top 200 
genes to known metabolic and signaling pathways. The three pathways that were most 
highly correlated with this set of potentially novel gene – cancer diagnosis relationships 
were all inflammatory pathways (i.e. the Acute Phase Response Signaling Pathway, the 
Glucocorticoid Signaling Pathway and the Hepatic Fibrosis Pathway). This finding 
highlights the importance of inflammation as a stimulus for the transformation of normal 
tissue to malignancy. Perhaps the common basis for transformation of cells to malignancies 
has already been published but remains “hidden” within synergies between articles within 
the vast amounts of biomedical literature. This NLP based data mining experiment shows 
the utility of data mining the literature for scientific discovery. The authors believe that the 
entire medical literature should be exposed in this way to provide improved computable 
access to the knowledge contained in the text of the biomedical literature. Future research 
should include the addition of other journals content in the compendium used to find 
synergies across articles from the biomedical literature.
Our goal was to identify synergy between articles within the literature indicating potential 
relationships between genes or proteins and drugs or diseases that have heretofore not been 
previously recognized. This generated a marker discovery database that is searchable from 
multiple perspectives such that a disease-oriented researcher could search the disease they 
are interested in and find all of the genes, proteins and drugs associated with that disease 
organized by function. Alternatively, researchers could ask for all genes related to a 
medication. A clinical trialist might ask what new diseases might be treated by an existing 
medication. Researchers could either access this information with regard to known synergies 
(where the gene and disease have been mentioned in the same article) that verifies the utility 
of the algorithm or discontinuities (where the gene and disease have a functional 
relationship; however the two entities have never previously been mentioned in the same 
journal article). This may indicate the possibility of a novel relationship that can then be 
taken back to the bench for further definition, identification and research. Proteins and 
drugs, for example, that have a functional relationship but that have never been recognized to 
affect one another, may be candidates for further basic science analysis thereby leading to 
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more rapid marker and treatment discovery. We see this as a potential and very promising 
method for improving the research productivity.
This longitudinal research program aims to support the development of novel clinical and 
translational methods that can encompass a wide range of techniques including new methods 
of phenotyping where one could use SNOMED CT to phenotype the patients described in 
this paper. New biomarkers for research are a potential output of this project. In addition, 
this project may benefit clinical informatics for longitudinal studies that aim to rapidly look 
at specific associations that may lead to either additional retrospective analysis or 
prospective clinical trials. The special deliverable of this project is an interface where one 
can search the already recognized (concordant) relationships, and also disjoint or previously 
undocumented relationships between genes or proteins and drugs or diseases. As organizing 
concepts are included, searching for classes (e.g. concepts like beta blockers for drugs or 
cardiovascular diseases) will be possible without having to articulate the individual sub-
classes of information.
Although there are many other Ontologies available [16] and other literature which could be 
included in such an analysis, this study provides a proof of concept that useful synergies can 
be identified from the knowledge available across articles in the literature. A computable 
method for identifying these synergies has the potential to speed scientific discovery.
Biomedical Informatics has the potential to help us to uncover novel genetic linkage to 
human disease. This can lead to significant improvements in patient care with more swift 
knowledge discovery and translational research, bringing that knowledge more rapidly to the 
bedside and thereby empowering clinical implementation of personalized /individualized 
medicine.
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Illustrates the synergy between two journal articles, linking a gene to a disease through a 
common metabolic function.
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This figure depicts the connections between the top 200 novel cancer genes and the Acute 
Phase Response Signaling pathway. Nine of the genes that have metabolic functions 
associated with multiple cancers are found in this signaling pathway.
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Table 1
Top 50 Genes associated with Multiple Cancer Tissue Types and their annotations.
Gene Number of Cancers Annotation
MYELIN OLIGODENDROCYTE GLYCOPROTEIN 35 Neuro Tumors
LIPOPOLYSACCHARIDE BINDING PROTEIN 34 inflammatory; antimicrobial peptide LL-37 or Hcap 18 is a 
precursor.
CATHELICIDIN ANTIMICROBIAL PEPTIDE 34 Vascular Proliferation
POLYMERIC IMMUNOGLOBULIN RECEPTOR 33 Transports Immunoglobulin across cell membranes
TELOMERASE REVERSE TRANSCRIPTASE 32 Essential for transformation but inable to accomplish 
conversion on its own
DIHYDROPYRIMIDINE DEHYDROGENASE 31 Degrades 5-FU, deficiency leads to medulloblastoma, (Diasio 
- Auto Recessive Inheritance)
ORNITHINE CARBAMOYLTRANSFERASE 30 Trans-species; proliferation associated; Chemoprevention 
which can be an inhibitor of OTC (DMFO)
GASTRIC INHIBITORY POLYPEPTIDE 30 glucose-dependent insulinotropic polypeptide
HYPERGONADOTROPIC HYPOGONADISM 30 hypogonadism with elevated gonadotropins
UROPORPHYRINOGEN DECARBOXYLASE 30 PORPHYRIA CUTANEA TARDA
ASIALOGLYCOPROTEIN RECEPTOR 1 29 Hepatic Cell signaling - to Endoplasmic Reticulum
VASOACTIVE INTESTINAL PEPTIDE 29 VIP promotes TH2 differentiation and inhibits TH1 
responses by regulating macrophage costimulatory signals 
and probably IL12/IFN-gamma production; Decreases with 
Age.
PHOSPHOLIPID TRANSFER PROTEIN 29 polymorphisms caused decreased HDL; transcription factor-
binding motifs, SP1 and AP-2
DIHYDROOROTATE DEHYDROGENASE 28 catalyzes the fourth enzymatic step in de novo pyrimidine 
biosynthesis; For cell replication.
CILIARY NEUROTROPHIC FACTOR 27 Errors cause Weight Gain; some earlier presentation of ALS
ARYL HYDROCARBON RECEPTOR 25 Halogenated aromatic hydrocarbons cause cancer mediated 
by the enzme produced by this gene; basic helix-loop-
helix/PAS family transcription factors;regulates the effects of 
Estrogen Receptors
BREAKPOINT CLUSTER REGION 25 CML
PHENYLALANINE HYDROXYLASE 25 PKU
PHOSPHOGLYCERATE KINASE 1 25 functions in glycolysis but is secreted by tumor cells and 
participates in the angiogenic process as a disulfide 
reductase; anti-angiogenic and slows tumor growth; 
deficiency causes hemolytic anemia
ISLET AMYLOID POLYPEPTIDE 25 diabetes Mellitus type 1 and 2, Insulinoma,
CHOLINE ACETYLTRANSFERASE 25 deficiency causes myasthenic symptoms
NUCLEOSIDE PHOSPHORYLASE 24 deficiency led to lymphoma, lymphopenia,
LEUKOTRIENE A4 HYDROLASE 24 inflammatory mediator, rarely in African Americans
GLUTATHIONE PEROXIDASE 1 24 Hemolytic Anemia, 6 copy repeats associated with myeloid 
leukemias
PROSTAGLANDIN E SYNTHASE 24 A p53 induced gene; PIG12 gene (synonym) encodes a 
microsomal glutathione S-transferase; is anti-inflammatory 
and can lead to apoptosis. Can improve Hepatocellular 
carcinoma by blocking PG1 and PG3 receptors.
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Gene Number of Cancers Annotation
ERYTHROPOIETIN RECEPTOR 23 proerythroblast cell lines that expressed Epor and had 
rearranged and inactivated expression of the p53 suppressor 
oncogene
GROWTH HORMONE RECEPTOR 23 leading to synthesis and secretion of insulin-like growth 
factor I ; GHR belongs to the cytokine superfamily of 
receptors that depend on JAK tyrosine kinases (see 147795) 
for activation of STATs
MELANOCORTIN 4 RECEPTOR 23 decreases body weight.
LEUKOTRIENE C4 SYNTHASE 23 potent lipid mediators of tissue inflammation
ARGININOSUCCINATE LYASE 23 deficiency results in defective cleavage of Argininosuccinic 
acid (ASA), a precursor to fumarate in the citric acid cycle, 
which causes accumulation of ASA in cells and an excessive 
excretion of ASA in urine (arginosuccinic aciduria). 
Deficiency characterized by hyperammonemia in affected 
individuals.
HISTIDINE DECARBOXYLASE 23 the only histamine-synthesizing enzyme; mouse models w/ 
gene removed are characterized by undetectable tissue 
histamine levels.
DIHYDROFOLATE REDUCTASE 23 converts Dihydrofolic acid (vitamin B9), which interacts with 
bacteria during cell division and can be targeted with drug 
analogs to prevent nucleic acid synthesis, to tetrahydrofolic 
acid.
ADENOSINE A2A RECEPTOR 22 a potent biologic mediator that modulates the activity of 
numerous cell types, including various neuronal populations, 
platelets, neutrophils and mast cells, and smooth muscle cells 
in bronchi and vasculature, helping to protect cells and 
tissues during stress situations such as ischemia. Abundant in 
basal ganglia, vasculature and platelets, and stimulates 
adenylyl cyclase. It is a major target of caffeine. Knockout 
mouse models show reduced exploratory activity, and 
caffeine, which normally stimulates exploratory behavior, 
became a depressant of exploratory activity. They scored 
higher in anxiety tests, and male mice were more aggressive 
toward intruders. Their response to acute pain stimuli was 
slower. Blood pressure and heart rate were increased, as well 
as platelet aggregation. The specific A2a agonist CGS 21680 
lost its biologic activity in all systems tested.
TRANSFERRIN RECEPTOR 2 22 Mediates cellular uptake of transferrin-bound iron in a non-
iron dependent manner. May be involved in iron metabolism, 
hepatocyte function and erythrocyte differentiation. Defects 
in TFR2 are a cause of hereditary hemochromatosis type 3 
(HFE3) [MIM:604250]. HFE3 is a disorder of iron 
hemostasis resulting in iron overload and has a phenotype 
indistinguishable from that of hereditary hemochromatosis 
(HH). HH is characterized by abnormal intestinal iron 
absorption and progressive increase of total body iron, which 
results in midlife in clinical complications including 
cirrhosis, cardiopathy, diabetes, endocrine dysfunctions, 
arthropathy, and susceptibility to liver cancer. Since the 
disease complications can be effectively prevented by regular 
phlebotomies, early diagnosis is most important to provide a 
normal life expectancy to the affected subjects.
INTERLEUKIN 4 RECEPTOR 22 mutation has been associated with increased IgE production 
and allergic airway inflammation
INTERLEUKIN 6 RECEPTOR 22 patients with allergic asthma had increased levels of soluble 
IL6R (sIL6R) in their airways compared with controls
PROMYELOCYTIC LEUKEMIA 22 regulates the p53 response to oncogenic signals. The gene is 
often involved in the translocation with the retinoic acid 
receptor alpha gene associated with acute promyelocytic 
leukemia
PANCREATIC POLYPEPTIDE 22 may be important in regulation of food intake; genetically 
obese laboratory animals have altered PPY release and in 
New Zealand obese mice weight gain can be cured by 
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Gene Number of Cancers Annotation
infusion of PPY. Children with Prader-Willi syndrome have 
blunted secretion of PPY
THYMIDYLATE SYNTHETASE 22 enzyme used to generate thymidine monophosphate (dTMP), 
which is subsequently phosphorylated to thymidine 
triphosphate for use in DNA synthesis and repair
DEOXYHYPUSINE SYNTHASE 22 inhibition suppresses retroviral replication in cell culture and 
primary cells with no measurable drug-induced adverse 
effects on cell cycle transition, apoptosis, or general 
cytotoxicity.
XANTHINE DEHYDROGENASE 22 Xdh-null mice were runted and did not live beyond 6 weeks 
of age. Xdh heterozygous females, although healthy and 
fertile, were unable to maintain lactation, and their pups died 
of starvation 2 weeks postpartum. Histologic analysis showed 
that, in heterozygous females, the mammary epithelium had 
collapsed, resulting in premature involution of the mammary 
gland. Electron microscopy showed that Xdh was specifically 
required for enveloping milk fat droplets with the apical 
plasma membrane prior to secretion from the lactating 
mammary gland.
SORBITOL DEHYDROGENASE 22 converts sorbitol to fructose and sorbitol is implicated in 
diabetic cataracts
SPLEEN TYROSINE KINASE 22 SYK is activated by oxidative stress; putative tumor 
suppressor; role in the differentiation of B-cells and many 
other cell types; inactivated by hyper- methylation. Found to 
be inactivated in a subset of breast cancer. also prevalent in a 
case of myelodysplastic syndrome.
ANKYLOSING SPONDYLITIS 22 mainly affects joints in the spine and the sacroilium in the 
pelvis, and can cause eventual fusion of the spine.
EOSINOPHIL PEROXIDASE 21 patially responsible for tissue remodeling; provides 
mechanism by which eosinophils kill multicellular parasites 
(eg, the nematode worms involved in filariasis); and also 
certain bacteria (eg tuberculosis bacteria)
HYALURONAN SYNTHASE 3 21 regulator of hyaluronan synthesis, major constituent of 
extracellular matrix
ADENOSINE A3 RECEPTOR 21 expressed at high levels in the vascular smooth muscle layer 
of normal mouse aortas. knockout mice showed blood 
pressure comparable to WT, but aorta and heart cAMP levels 
were elevated. When challenged with adenosine, the KO 
mice showed further increased cAMP levels in the heart and 
vascular smooth muscle, and a significant decrease in blood 
pressure.
HISTONE DEACETYLASE 2 21 KO mice are characterized by partially penetrant embryonic 
lethality, with abnormalities of myocyte proliferation and 
differentiation apparent during late gestation
HISTONE DEACETYLASE 4 21 regulates chondrocyte hypertrophy and endochondral bone 
formation in mice by interacting with and inhibiting the 
activity of Runx2 (600211), a transcription factor necessary 
for chondrocyte hypertrophy
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Table 2
The Signaling pathways reviewed and the number of Genes associated with each pathway from this potentially 
novel cancer related dataset.
Signaling Pathways Number of genes in common
Actin Cytoskeleton Signaling 2
Acute Phase Response Signaling 7
Amyotrophic Lateral Sclerosis Signaling 1
Antigen Presentation Pathway 1
Aryl Hydrocarbon Receptor Signaling 5
B Cell Receptor Sgnaling 1
BMP signaling pathway 1
Calcium Signalng 1
Cell Cycle: G1/S Checkpoint Regulation 1
Geramide Signaling 1
Circadian Rhythm Signaling 1
Coagulation System 3
Complement System 2




Estrogen Receptor Signaling 2
Fc Epsilon Signaling 3
FXR/RXR Activation 4
Glucocorticoid Receptor Signaling 9
Glutamate Receptor Signaling 1
Hepatic Cholestasis
Hepatic Fibrosis/Hepatic Stellate Cell Activation 9
Huntington’s Disease Signaling 3





Insulin Receptor Signaling 1
Interferon Signaling 1
LPS/IL-1 Mediated Inhibtion of RXR Function 3
LXR/RXR Activation 5
Mitcochondrial Dysfunction 4
NRF2-mediated Oxidative Stress Response 3
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Role of BRCA1 in DNA Damage Response 1
T Cell Receptor Signaling 1
Toll-Like Receptor Signaling 1
TR/RXR Activation 2
VDR/RXR Activation 5
Xenobiotic Metabolism Signaling 1
T Cell Receptor Signaling 1
Toll-Like Receptor Signaling 1
TR/RXR Activation 2
VDR/RXR Activation 5
Xenobiotic Metabolism Signaling 1
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